Catalog No.
DHJ67201
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
Fusion - [Human FGF21 analog]2 - IGHG1 Fc (Fragment constant)
Clonality
Monoclonal
Target
FGF21, Fibroblast growth factor 21, FGF-21
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
Q9NSA1
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
CVX-343, CVX 343, CVX343, PF-05231023
Clone ID
CVX-343
FGF21 analogue PF-05231023 on alcohol consumption and neuronal activity in the nucleus accumbens., PMID:40419727
PF-05231023 reduces lipid deposition in apolipoprotein E-deficient mice by inhibiting the expression of lipid synthesis genes., PMID:39144082
Epigenetic regulation of GABA catabolism in iPSC-derived neurons: The molecular links between FGF21 and histone methylation., PMID:37689244
[Improvement situation on indexes of the zebrafish disease model of non-alcoholic fatty liver disease with FGF21 analogues]., PMID:37580258
Hepatoprotective effects of the long-acting fibroblast growth factor 21 analog PF-05231023 in the GAN diet-induced obese and biopsy-confirmed mouse model of nonalcoholic steatohepatitis., PMID:36852934
FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit., PMID:35108517
Fibroblast growth factor 21 protects against lipotoxicity-induced pancreatic β-cell dysfunction via regulation of AMPK signaling and lipid metabolism., PMID:31654570
Fibroblast growth factors in control of lipid metabolism: from biological function to clinical application., PMID:30893110
FGF21 increases water intake, urine output and blood pressure in rats., PMID:30106981
Glyco-engineered Long Acting FGF21 Variant with Optimal Pharmaceutical and Pharmacokinetic Properties to Enable Weekly to Twice Monthly Subcutaneous Dosing., PMID:29523796
Fibroblast Growth Factor 21 Protects Photoreceptor Function in Type 1 Diabetic Mice., PMID:29487115
Process development of a FGF21 protein-antibody conjugate., PMID:28948603
Once-weekly administration of a long-acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non-human primates., PMID:28573777
PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates., PMID:27405817
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects., PMID:26959184
FGF21 does not require interscapular brown adipose tissue and improves liver metabolic profile in animal models of obesity and insulin-resistance., PMID:26153793
Pharmacokinetics and pharmacodynamics of PF-05231023, a novel long-acting FGF21 mimetic, in a first-in-human study., PMID:25940675
Mechanistic investigation of the preclinical pharmacokinetics and interspecies scaling of PF-05231023, a fibroblast growth factor 21-antibody protein conjugate., PMID:25805881
Pharmacokinetics (PK), pharmacodynamics (PD) and integrated PK/PD modeling of a novel long acting FGF21 clinical candidate PF-05231023 in diet-induced obese and leptin-deficient obese mice., PMID:25790234
Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody., PMID:23720456
For research use only. Not for human or drug use.
